The agreement grants LEO Pharma exclusive rights to the branded form of spesolimab for generalized pustular psoriasis and ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Boehringer Ingelheim and LEO Pharma have signed an exclusive global license and transfer agreement to commercialize and ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

The IL-36 inhibitor is being explored for additional inflammatory skin conditions, aiming to expand treatment options for underserved patient groups.

German family-owned pharma major Boehringer Ingelheim and Denmark’s LEO Pharma today announced an exclusive global license ...

SPEVIGO® is currently approved in 51 countries for treatment of GPP flares, and the CHMP opinion follows similar approvals for expanded and new indications in the US and China.

SPEVIGO ® is a novel, humanized, selective antibody that specifically blocks the activation of the IL-36R, a signaling pathway within the immune system shown to be involved in the pathogenesis of ...

Spevigo showed an acceptable safety profile, with no unexpected safety concerns. Burnam’s entrepreneurial odyssey began when, having studied behavioral neuroscience in grad school, he became a device ...